Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) have been given a consensus rating of “Moderate Buy” by the fifteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, ten have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $98.93.
ARWR has been the topic of a number of analyst reports. UBS Group began coverage on shares of Arrowhead Pharmaceuticals in a research note on Thursday, October 15th. They issued a “buy” rating and a $109.00 target price on the stock. Morgan Stanley raised their price target on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Citigroup began coverage on Arrowhead Pharmaceuticals in a report on Tuesday, September 8th. They set a “buy” rating and a $108.00 price objective on the stock. The Goldman Sachs Group assumed coverage on Arrowhead Pharmaceuticals in a research note on Thursday, September 24th. They issued a “neutral” rating and a $74.00 price objective on the stock. Finally, Piper Sandler reiterated an “overweight” rating and issued a $126.00 price objective (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 23rd.
Check Out Our Latest Stock Analysis on ARWR
Institutional Trading of Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Price Performance
NASDAQ:ARWR opened at $44.21 on Tuesday. The company has a debt-to-equity ratio of 1.77, a quick ratio of 5.90 and a current ratio of 5.90. The company has a 50-day moving average of $62.48 and a 200-day moving average of $70.90. Arrowhead Pharmaceuticals has a 52 week low of $37.06 and a 52 week high of $95.49. The company has a market capitalization of $6.23 billion, a price-to-earnings ratio of -8.65 and a beta of 1.34.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues. The company’s research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.
Read More
- Five stocks we like better than Arrowhead Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
